SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
CBIO reported Three months ended September 30, 2026 results. The stock moved -1.5% on the print.
CBIOearnings

Earnings reactions, page 3

Crescent Biopharma, Inc. (CBIO) FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • License agreement revenue was $3,117 thousand for the three months ended September 30, 2026, compared to $0 for the three months ended September 30, 2025.
  • Research and development expenses were $34.3 million for the three months ended September 30, 2026, compared to $20.3 million for the three months ended September 30, 2025.
  • General and administrative expenses were $8.7 million for the three months ended September 30, 2026, compared to $5.5 million for the three months ended September 30, 2025.
  • Net loss was $37.7 million, or $0.90 per basic and diluted share, for the three months ended September 30, 2026, compared to $24.6 million, or $1.27 per basic and diluted share, for the three months ended September 30, 2025.
  • Cash and cash equivalents were $289.4 million as of September 30, 2026.

Guidance

  • Crescent expects that its existing cash and cash equivalents will fund operations into the second half of 2028.

Price and volatility reaction

The stock moved -1.5% on the print. No front-expiry chain was on file, so there is no straddle expected move.

MeasureValueBasis
Close before release14.372026-11-12
Close after release14.152026-11-13
Realised move-1.5%close to close
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →